Faculty profile

Andrew Robinson

Back to faculty

ResearcherCancer Care and EpidemiologyQueen's University

This profile was built from research grant records and is no longer listed. The details below may be out of date.

Andrew Robinson

Researcher

Cancer Care and Epidemiology

Queen's University

Kingston, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
12 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2019.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

297

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Advanced Cancer Discrete Choice Experiement Overall Survival Patient Values Progression-Free Survival Systemic Therapy Trade-Off Methods

Latest papers

Real-world uptake of neoadjuvant chemoimmunotherapy and surgery in patients with stage II-IIIB non-small cell lung cancer.
Frontiers in oncology · 2026
Balancing Innovation and Safety: Prediction, Prevention, and Management of Pneumonitis in Lung Cancer Patients Receiving Novel Anti-Cancer Agents.
Cancers · 2025
Health care system factors associated with receipt of treatment and treatment intent in stage III non-small cell lung cancer: A population-based study in Ontario.
Clinical and translational radiation oncology · 2025

All 36 publications

Latest funding

Understanding how cancer patients value progression-free survival
CIHR · 2019 · Principal investigator
$175,951
Real world outcomes of novel targeted agents for the treatment of metastatic HER-2 positive breast cancer in Ontario: A population-based study
CIHR · 2018 · Co-investigator
$97,999
Can Early Palliative Care for Non-Small Cell Lung Cancer Improve End-of-Life Outcomes and Reduce Cost in the Real World? A Population-Based Study
CIHR · 2017 · Co-investigator
$74,853

All 3 grants and awards

36 publications.

Real-world uptake of neoadjuvant chemoimmunotherapy and surgery in patients with stage II-IIIB non-small cell lung cancer.

Norman C, Giles A, Robinson A, Mates M, Genta S, Al Sibani M, Thanabalachandran L, Jafari D, Hopman W, Li Y

Frontiers in oncology2026

DOI: 10.3389/fonc.2026.1870140 PMID: 42597410

Balancing Innovation and Safety: Prediction, Prevention, and Management of Pneumonitis in Lung Cancer Patients Receiving Novel Anti-Cancer Agents.

Liu S, Wang D, Robinson A, Mates M, Li Y, Chooback N, Gaudreau PO, Digby GC, Fung AS, Genta S

Cancers2025

DOI: 10.3390/cancers17152522 PMID: 40805219

Health care system factors associated with receipt of treatment and treatment intent in stage III non-small cell lung cancer: A population-based study in Ontario.

Thibodeau S, Nguyen P, Robinson A, Moraes FY, Pantarotto J, Hanna TP

Clinical and translational radiation oncology2025

DOI: 10.1016/j.ctro.2024.100873 PMID: 39677000

Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy

Di Pastena F, Pond G, Tsakiridis EE, Gouveia A, Ahmadi E, Biziotis O-D, Ali A, Swaminath A, Okawara G, Ellis PM

Radiation Oncology20245 citations

DOI: 10.1186/s13014-024-02546-y

Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.

Bar J, Esteban E, Rodríguez-Abreu D, Aix SP, Szalai Z, Felip E, Gottfried M, Provencio M, Robinson A, Fülöp A, Rao SB, Camidge DR, Speranza G, Townson SM, Kobie J, Ayers M, Dettman EJ, Hunkapiller N, McDaniel R, Jung B, Burkhardt D, Mauntz R, Csőszi T

Lung cancer (Amsterdam, Netherlands)2024

DOI: 10.1016/j.lungcan.2024.107506 PMID: 38422883

Patients' considerations of time toxicity when assessing cancer treatments with marginal benefit.

Gupta A, Brundage MD, Galica J, Karim S, Koven R, Ng TL, O'Donnell J, tenHove J, Robinson A, Booth CM

The oncologist2024

DOI: 10.1093/oncolo/oyae187 PMID: 39045654

Factors Influencing the Timeliness and Completeness of Appropriate Staging Investigations for Patients with Stage I-III Lung Cancer in Southeastern Ontario.

AlGhamdi S, Ahimsadasan N, Kong W, Brundage M, Eisenhauer EA, Parker CM, Robinson A, Giles A, Digby GC

Current oncology (Toronto, Ont.)2024

DOI: 10.3390/curroncol31100453 PMID: 39451757

Brief Report: Real-World Eligibility for Clinical Trials in Patients With Extensive-Stage SCLC at a Tertiary Care Center.

Dehar N, Meem M, Aggarwal I, Hopman W, Gaudreau PO, Robinson A, Fung AS

JTO clinical and research reports2024

DOI: 10.1016/j.jtocrr.2024.100696 PMID: 39091596

Can Oncogenic Driver Alterations be Responsible for the Lack of Immunotherapy Efficacy in First-line Advanced Urothelial Carcinoma?

Kartolo A, Robinson A, Vera Badillo FE

European Urology20233 citations

DOI: 10.1016/j.eururo.2022.04.022

Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center

Thibodeau S, Meem M, Hopman W, Sandhu S, Zalay O, Fung AS, Kartolo A, Digby GC, Al-Ghamdi S, Robinson A

Cancer Treatment and Research Communications2023

DOI: 10.1016/j.ctarc.2023.100747

Something wrong or missing on this profile? Suggest a correction

Andrew Robinson

Research

Latest papers

Latest funding

Real-world uptake of neoadjuvant chemoimmunotherapy and surgery in patients with stage II-IIIB non-small cell lung cancer.

Balancing Innovation and Safety: Prediction, Prevention, and Management of Pneumonitis in Lung Cancer Patients Receiving Novel Anti-Cancer Agents.

Health care system factors associated with receipt of treatment and treatment intent in stage III non-small cell lung cancer: A population-based study in Ontario.

Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy

Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.

Patients' considerations of time toxicity when assessing cancer treatments with marginal benefit.

Factors Influencing the Timeliness and Completeness of Appropriate Staging Investigations for Patients with Stage I-III Lung Cancer in Southeastern Ontario.

Brief Report: Real-World Eligibility for Clinical Trials in Patients With Extensive-Stage SCLC at a Tertiary Care Center.

Can Oncogenic Driver Alterations be Responsible for the Lack of Immunotherapy Efficacy in First-line Advanced Urothelial Carcinoma?

Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center

Understanding how cancer patients value progression-free survival

Real world outcomes of novel targeted agents for the treatment of metastatic HER-2 positive breast cancer in Ontario: A population-based study

Can Early Palliative Care for Non-Small Cell Lung Cancer Improve End-of-Life Outcomes and Reduce Cost in the Real World? A Population-Based Study

Frequent collaborators

Mark Clemons

John Hilton

Brian Hutton

Dean Fergusson

Adi Kartolo

Gregory Pond

Peter Ellis

Jacqueline Galica

Angel Arnaout

Marcin Wierzbicki

Anand Swaminath

Gordon Okawara

Theos Tsakiridis

Michael Brundage

Michael Ong

Sharon McGee

Eitan Amir

Paul Wheatley-Price

Dongsheng Tu

Jason Pantarotto

Christina Canil

Geoffrey Liu

Sebastien Hotte

Gregory Steinberg

Ming-Sound Tsao

Christopher Booth

Kednapa Thavorn

Madhuri Koti

Rylan Egan

Josee-Lyne Ethier